Company opens new office to serve as the company’s Asia-Pacific headquarters
PHILADELPHIA – (OCTOBER 14, 2016) – InClinica, a global, clinical CRO, announced the opening of its new Asia-Pacific office in Kuala Lumpur, along with its subsidiary company, IC LifeSciences.
The new Kuala Lumpur office will serve as InClinica’s Asia-Pacific headquarters ? the hub for clinical research and life science business development in the region. Jeffrey S. Yablon, executive vice president of InClinica and IC LifeSciences, will serve as the head of this location.
“InClinica prides itself on the depth of our connections around the globe,” said James Nolan, CEO of InClinica. “Our goal with the new office was to build upon our already solid presence in the Asia-Pacific region. We are adding another layer of depth to our services and further proving our commitment to building a sustainable, global company.”
InClinica launched in 2016 following the acquisition of an existing clinical research organization.
About InClinica
InClinica is a global clinical contract research organization founded in 2016 after the acquisition of an existing global CRO. With a senior management team that brings more than 100 combined years of experience, InClinica works across all phases of the clinical research process and has a particular strength in first in man and phase 2 studies. InClinica is headquartered in Philadelphia with other locations in the U.K., Israel, and Malaysia/Singapore.
